Furthermore, targeted inhibition of GRP suppressed the activation of the AKT/mTOR signaling cascade and transcription of critical oncogenes involved in neuroblastoma progression, specifically MYCN, TWIST and FAK. It is well established that MYCN amplification is one of the strongest predictors of advanced disease, tumor progression and poor clinical outcome in patients with neuroblastoma [17]. This evidence concerns the gene TWIST1 and neuroblastoma.